FDA to accelerate Exjade review

The FDA has agreed to give Novartis a priority review for Exjade, an experimental treatment that removes excess iron in the blood. And analysts say the move may allow the drug giant to start marketing the drug by the end of this year. Potential sales estimates range from $200 million to $700 million a year.

- read this story from MarketWatch for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.